Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01192568 · ClinicalTrials.gov registry record · Phase 4
Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder
A Phase 4 study of Neurogenic Bladder and Overactive Detrusor, sponsored by AbbVie.
- Completed
- Registry status
- Phase 4
- Development phase
- 52
- Enrollment target
- 10
- Study locations
NCT01192568 is a Phase 4 study of Neurogenic Bladder and Overactive Detrusor that has completed, run by AbbVie. The registered enrollment target is 52 participants, below the 90-participant average among 16 other Neurogenic Bladder trials with a reported enrollment target (42% lower). The trial reports 10 study locations across 9 states.
The verdict
NCT01192568, a Phase 4 study of Neurogenic Bladder and Overactive Detrusor, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 52 participants
- Enrollment target
- 10
- Study locations
Study Summary
This study will evaluate the safety and efficacy of Oxybutynin Chloride 10% Topical Gel in children 3 to less than 17 years old, who have overactive bladder due to a neurogenic condition. Children will be treated with 0.75 g of gel/day for two weeks. Patients will then return to the clinic for a potential dose titration. At this time their dose may be adjusted up to 1g/day, down to 0.5g/day, or remain the same at 0.75g of gel/day depending on the individual response and tolerability. The total treatment time is 14 weeks and total time on the study is 16 weeks.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Oxybutynin
Study Locations (10)
California
- Loma Linda University /ID# 236889 - Loma Linda
- Child Hosp of Orange County,CA /ID# 237517 - Orange
Colorado
- Children's Hospital Colorado - Aurora /ID# 237620 - Aurora
Georgia
- Augusta University Medical Center /ID# 238188 - Augusta
Mississippi
- University of Mississippi Medical Center /ID# 238065 - Jackson
New York
- Albany Medical College /ID# 236880 - Albany
North Carolina
- Duke University /ID# 237494 - Durham
Oregon
- Duplicate_Oregon Health & Science University /ID# 234354 - Portland
Texas
- Cook Children's Med. Center /ID# 237538 - Fort Worth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2011-05-17 |
| Est. Completion | 2023-10-24 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01192568
The ClinicalTrials.gov registry entry for NCT01192568 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 90-participant average among 16 other Neurogenic Bladder trials with a reported enrollment target (42% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Neurogenic Bladder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01192568 reports 10 study locations spanning 9 distinct geographic areas - top geographies include California, Colorado, Georgia.
Frequently Asked Questions
What is clinical trial NCT01192568 about?
NCT01192568 is a clinical study titled "Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder". This study will evaluate the safety and efficacy of Oxybutynin Chloride 10% Topical Gel in children 3 to less than 17 years old, who have overactive bladder due to a neurogenic condition. Children will be treated with 0.75 g of gel/day for two weeks. Patients will then return to the clinic for a pot...
What is the current status of trial NCT01192568?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 52 participants. The study started on 2011-05-17. Estimated completion is 2023-10-24.
What conditions does trial NCT01192568 study?
This clinical trial studies the following conditions: Neurogenic Bladder, Overactive Detrusor.
What interventions are being tested in trial NCT01192568?
The interventions under investigation include: Placebo (DRUG), Oxybutynin (DRUG).
Who is sponsoring clinical trial NCT01192568?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01192568 being conducted?
This trial has 10 study locations across California, Colorado, Georgia, Mississippi, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neurogenic Bladder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Intravesical Lactobacillus Crispatus: Clinical Safety and Microbiome Evaluation
RECRUITING · Early Phase 1
-
Patient and Caregiver Perspectives on Intravesical Instillations for Urinary Symptoms
RECRUITING
-
Intravesical LGG VS Saline Bladder Wash RCT
RECRUITING · Phase 2
-
Neuromodulating Cortical Regions Involved in Neurogenic Bladder in MS
RECRUITING · NA
-
Vascularized Composite Bladder Allograft Transplantation
RECRUITING · NA
-
Concomitant Renal and Urinary Bladder Allograft Transplantation
RECRUITING · Early Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.